Lilly gets rare downgrade as analysts question hype over GLP-1 pills and Zepbound’s cash sales - MarketWatch
Lilly gets rare downgrade as analysts question hype over GLP-1 pills and Zepbound’s cash sales MarketWatch
Zepbound News
Eli Lilly Just Opened the Door to Even Greater GLP-1 Growth - 24/7 Wall St.
Eli Lilly Just Opened the Door to Even Greater GLP-1 Growth 24/7 Wall St.
Compounded version of Eli Lilly GLP-1 may have impurity, company warns - NewsNation
Compounded version of Eli Lilly GLP-1 may have impurity, company warns NewsNation
When Weight-Loss Drugs Don’t Work - The New York Times
When Weight-Loss Drugs Don’t Work The New York Times
The next wave of GLP-1 drugs are coming—and they’re stronger than Wegovy and Zepbound - Scientific American
The next wave of GLP-1 drugs are coming—and they’re stronger than Wegovy and Zepbound Scientific American
Eli Lilly blows past quarterly estimates, posts strong outlook as Zepbound and Mounjaro sales soar - CNBC
Eli Lilly blows past quarterly estimates, posts strong outlook as Zepbound and Mounjaro sales soar CNBC
Study raises red flags over long-term effectiveness of popular weight loss drugs like Ozempic - ScienceDaily
Study raises red flags over long-term effectiveness of popular weight loss drugs like Ozempic ScienceDaily
Media Statement: Zepbound (tirzepatide) KwikPen now available at self-pay pricing at major pharmacies nationwide in addition to LillyDirect - Eli Lilly and Company
Media Statement: Zepbound (tirzepatide) KwikPen now available at self-pay pricing at major pharmacies nationwide in addition to LillyDirect Eli Lilly and Company
Lilly Flags Safety Risk in Compounded Zepbound Mixed With Vitamin B12 - Bloomberg.com
Lilly Flags Safety Risk in Compounded Zepbound Mixed With Vitamin B12 Bloomberg.com
Kroger brings Zepbound KwikPen to pharmacy, expanding access & savings for self-pay patients - The Hamilton County Reporter
Kroger brings Zepbound KwikPen to pharmacy, expanding access & savings for self-pay patients The Hamilton County Reporter
Lilly warns GLP-1 knockoffs may be ‘dangerous,’ escalating war with compounders - BioPharma Dive
Lilly warns GLP-1 knockoffs may be ‘dangerous,’ escalating war with compounders BioPharma Dive
Multi-Dose KwikPen Now Available for Zepbound Administration - Gastroenterology Advisor
Multi-Dose KwikPen Now Available for Zepbound Administration Gastroenterology Advisor
Amazon Pharmacy Expands Access to Zepbound KwikPen - Progressive Grocer
Amazon Pharmacy Expands Access to Zepbound KwikPen Progressive Grocer
Eli Lilly launches program for employers to subsidize cost of obesity drug outside insurance - statnews.com
Eli Lilly launches program for employers to subsidize cost of obesity drug outside insurance statnews.com
Eli Lilly launches new form of obesity drug Zepbound with a month’s worth of doses in one pen - CNBC
Eli Lilly launches new form of obesity drug Zepbound with a month’s worth of doses in one pen CNBC
Why it’s easier and cheaper for you to buy GLP-1s - The Washington Post
Why it’s easier and cheaper for you to buy GLP-1s The Washington Post
In latest compounding clash, Lilly flags high levels of 'impurity' in tirzepatide knockoffs with vitamin B12 - Fierce Pharma
In latest compounding clash, Lilly flags high levels of 'impurity' in tirzepatide knockoffs with vitamin B12 Fierce Pharma
Zepbound vs. Wegovy: Which Weight Loss Treatment Comes Out on Top? - Everyday Health
Zepbound vs. Wegovy: Which Weight Loss Treatment Comes Out on Top? Everyday Health
Kroger Expands Access to Multi-Dose GLP-1 Therapy with Zepbound KwikPen - Pharmaceutical Commerce
Kroger Expands Access to Multi-Dose GLP-1 Therapy with Zepbound KwikPen Pharmaceutical Commerce
Figuring: Eating With My Daughter and My Zepbound - The Cut
Figuring: Eating With My Daughter and My Zepbound The Cut
FDA approves label expansion for Zepbound to be used with Eli Lilly’s KwikPen - Healio
FDA approves label expansion for Zepbound to be used with Eli Lilly’s KwikPen Healio
Eli Lilly Launches Zepbound KwikPen Multi-Dose Tirzepatide Pen for Adults With Obesity - HCPLive
Eli Lilly Launches Zepbound KwikPen Multi-Dose Tirzepatide Pen for Adults With Obesity HCPLive
Zepbound (tirzepatide), the most prescribed weight management medication in 2025, now available in multi-dose KwikPen - Eli Lilly and Company
Zepbound (tirzepatide), the most prescribed weight management medication in 2025, now available in multi-dose KwikPen Eli Lilly and Company
An open letter from Eli Lilly and Company warning of potential patient safety risks associated with tirzepatide compounded with vitamin B12 - Eli Lilly and Company
An open letter from Eli Lilly and Company warning of potential patient safety risks associated with tirzepatide compounded with vitamin B12 Eli Lilly and Company
Amazon Pharmacy Expands Access to Eli Lilly’s Zepbound KwikPen for Weight Management - Yahoo Finance
Amazon Pharmacy Expands Access to Eli Lilly’s Zepbound KwikPen for Weight Management Yahoo Finance
Kroger pharmacies offer Zepbound KwikPen - Drug Store News
Kroger pharmacies offer Zepbound KwikPen Drug Store News
Amazon Pharmacy Expands Access to Eli Lilly’s Zepbound KwikPen for Weight Management - Business Wire
Amazon Pharmacy Expands Access to Eli Lilly’s Zepbound KwikPen for Weight Management Business Wire
Regeneron's obesity drug shows Zepbound-like efficacy in phase 3 - Fierce Biotech
Regeneron's obesity drug shows Zepbound-like efficacy in phase 3 Fierce Biotech
Novo Nordisk’s next-gen obesity drug stumbles in comparison study - statnews.com
Novo Nordisk’s next-gen obesity drug stumbles in comparison study statnews.com
Zepbound ended my food obsession. Medicaid won't cover it. | Letters - IndyStar
Zepbound ended my food obsession. Medicaid won't cover it. | Letters IndyStar
Lilly’s KwikPen Delivers Month of Zepbound GLP-1 in One Device - Packaging Digest
Lilly’s KwikPen Delivers Month of Zepbound GLP-1 in One Device Packaging Digest
Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together delivered superior efficacy in first-of-its-kind Phase 3b trial for adults with psoriasis and obesity or overweight - Eli Lilly and Company
Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together delivered superior efficacy in first-of-its-kind Phase 3b trial for adults with psoriasis and obesity or overweight Eli Lilly and Company
Novo Nordisk’s CagriSema bested by Lilly’s Zepbound in head-to-head trial - Clinical Trials Arena
Novo Nordisk’s CagriSema bested by Lilly’s Zepbound in head-to-head trial Clinical Trials Arena
New Zepbound weight-loss pen at Kroger aims to cut self-pay costs - Stock Titan
New Zepbound weight-loss pen at Kroger aims to cut self-pay costs Stock Titan
Lilly adds multidose Zepbound pens to self-pay menu after FDA nod - Fierce Pharma
Lilly adds multidose Zepbound pens to self-pay menu after FDA nod Fierce Pharma
Eli Lilly launches new weight-loss drug Zepbound KwikPen: What to know - Good Morning America
Eli Lilly launches new weight-loss drug Zepbound KwikPen: What to know Good Morning America
Lilly courts employers in new push to broaden Zepbound access - FirstWord Pharma
Lilly courts employers in new push to broaden Zepbound access FirstWord Pharma
Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together delivered superior efficacy in first-of-its-kind Phase 3b trial for adults with active psoriatic arthritis and obesity or overweight | Eli Lilly and Company - Eli Lilly and Company
Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together delivered superior efficacy in first-of-its-kind Phase 3b trial for adults with active psoriatic arthritis and obesity or overweight | Eli Lilly and Company Eli Lilly and Company
Eli Lilly’s Zepbound Gets FDA OK for Multi-Dose Pen - WSJ
Eli Lilly’s Zepbound Gets FDA OK for Multi-Dose Pen WSJ
Lilly's Zepbound and Taltz improve psoriasis symptoms, drive weight loss in study - CNBC
Lilly's Zepbound and Taltz improve psoriasis symptoms, drive weight loss in study CNBC